145 related articles for article (PubMed ID: 34441043)
1. Low KIBRA Expression Is Associated with Poor Prognosis in Patients with Triple-Negative Breast Cancer.
Kim SW; Chu J; Do SI; Na K
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441043
[No Abstract] [Full Text] [Related]
2. Low expression of WWC1, a tumor suppressor gene, is associated with aggressive breast cancer and poor survival outcome.
Wang Z; Katsaros D; Biglia N; Shen Y; Fu Y; Tiirikainen M; Yu H
FEBS Open Bio; 2019 Jul; 9(7):1270-1280. PubMed ID: 31102318
[TBL] [Abstract][Full Text] [Related]
3. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
[TBL] [Abstract][Full Text] [Related]
4.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
5. KIBRA (WWC1) Is a Metastasis Suppressor Gene Affected by Chromosome 5q Loss in Triple-Negative Breast Cancer.
Knight JF; Sung VYC; Kuzmin E; Couzens AL; de Verteuil DA; Ratcliffe CDH; Coelho PP; Johnson RM; Samavarchi-Tehrani P; Gruosso T; Smith HW; Lee W; Saleh SM; Zuo D; Zhao H; Guiot MC; Davis RR; Gregg JP; Moraes C; Gingras AC; Park M
Cell Rep; 2018 Mar; 22(12):3191-3205. PubMed ID: 29562176
[TBL] [Abstract][Full Text] [Related]
6. KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy.
Mudduwa L; Peiris H; Gunasekara S; Abeysiriwardhana D; Liyanage N; Rayala SK; Liyanage T
BMC Cancer; 2018 May; 18(1):589. PubMed ID: 29793439
[TBL] [Abstract][Full Text] [Related]
7. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of survivin and EGFR protein expression in triple-negative breast cancer (TNBC) patients.
Zhang M; Zhang X; Zhao S; Wang Y; Di W; Zhao G; Yang M; Zhang Q
Target Oncol; 2014 Dec; 9(4):349-57. PubMed ID: 24233638
[TBL] [Abstract][Full Text] [Related]
9. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
10. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of aldehyde dehydrogenase 1 (ALDH1) in invasive breast carcinomas.
Demir H; Dulgar O; Gulle BT; Turna H; Ilvan S
Bosn J Basic Med Sci; 2018 Nov; 18(4):313-319. PubMed ID: 29924962
[TBL] [Abstract][Full Text] [Related]
12. Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer.
Bastiaansen AEM; Timmermans AM; Smid M; van Deurzen CHM; Hulsenboom ESP; Prager-van der Smissen WJC; Foekens R; Trapman-Jansen AMAC; Sillevis Smitt PAE; Luider TM; Martens JWM; vanDuijn MM
Sci Rep; 2020 Dec; 10(1):22292. PubMed ID: 33339858
[TBL] [Abstract][Full Text] [Related]
13. Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.
Yi J; Ren L; Li D; Wu J; Li W; Du G; Wang J
Biomed Pharmacother; 2020 Apr; 124():109827. PubMed ID: 31986408
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis regulator Bcl-2 is an independent prognostic marker for worse overall survival in triple-negative breast cancer patients.
Ozretic P; Alvir I; Sarcevic B; Vujaskovic Z; Rendic-Miocevic Z; Roguljic A; Beketic-Oreskovic L
Int J Biol Markers; 2018 Jan; 33(1):109-115. PubMed ID: 28777433
[TBL] [Abstract][Full Text] [Related]
15. Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy.
Honma N; Horii R; Ito Y; Saji S; Younes M; Iwase T; Akiyama F
BMC Cancer; 2015 Oct; 15():698. PubMed ID: 26472348
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
17. Identification and prognostic value of anterior gradient protein 2 expression in breast cancer based on tissue microarray.
Guo J; Gong G; Zhang B
Tumour Biol; 2017 Jul; 39(7):1010428317713392. PubMed ID: 28671019
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
[TBL] [Abstract][Full Text] [Related]
20. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer.
Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y
Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
